Secondary leukaemia after MMM combined modality therapy for breast carcinoma.
作者信息
Philpott N J, Bevan D H, Gordon-Smith E C
出版信息
Lancet. 1993 May 15;341(8855):1289. doi: 10.1016/0140-6736(93)91199-v.
PMID:8098437
Abstract
摘要
相似文献
1
Secondary leukaemia after MMM combined modality therapy for breast carcinoma.乳腺癌采用乳房改良根治术联合综合治疗后的继发性白血病
Lancet. 1993 May 15;341(8855):1289. doi: 10.1016/0140-6736(93)91199-v.
2
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.基于米托蒽醌的乳腺癌治疗后发生的继发性骨髓增生异常综合征/急性髓系白血病
Br J Cancer. 2000 Jul;83(1):91-4. doi: 10.1054/bjoc.2000.1196.
3
Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer.晚期乳腺癌接受3M（米托蒽醌、丝裂霉素和甲氨蝶呤）化疗后发生急性髓系白血病。
Leukemia. 1997 Dec;11(12):2211-3. doi: 10.1038/sj.leu.2400876.
4
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.以米托蒽醌为基础的大剂量化疗治疗原发性乳腺癌患者后发生的继发性急性白血病。
Bone Marrow Transplant. 2003 Dec;32(12):1153-7. doi: 10.1038/sj.bmt.1704291.
5
Secondary leukaemia after treating advanced bladder cancer with methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and radiotherapy.使用甲氨蝶呤、长春碱、阿霉素和顺铂化疗及放疗治疗晚期膀胱癌后发生的继发性白血病。
BJU Int. 2002 Sep;90(4):470-1. doi: 10.1046/j.1464-410x.2002.02866.x.
6
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?蒽环类药物与粒细胞集落刺激因子同时使用是否会影响乳腺癌女性患继发性白血病的风险？
Ann Oncol. 2005 Jul;16(7):1209-10. doi: 10.1093/annonc/mdi201. Epub 2005 Apr 27.
7
Mitoxantrone, mitomycin-C, methotrexate combination chemotherapy with radiotherapy and/or surgery in stage III (T4B, NO-2, M0) breast cancer.米托蒽醌、丝裂霉素-C、甲氨蝶呤联合化疗并结合放疗和/或手术治疗Ⅲ期（T4B，NO-2，M0）乳腺癌。
J Assoc Physicians India. 1998 Nov;46(11):926-9.
8
Chronic myeloid leukemia following cyclophosphamide-containing chemotherapy in a breast cancer patient.一名乳腺癌患者在接受含环磷酰胺化疗后发生慢性髓系白血病。
Haematologica. 1993 Jan-Feb;78(1):56-7.
9
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.米托蒽醌/甲氨蝶呤/丝裂霉素C（MMM）与环磷酰胺/甲氨蝶呤/5-氟尿嘧啶（CMF）治疗晚期乳腺癌的随机对照试验。
Br J Cancer. 1991 May;63(5):794-8. doi: 10.1038/bjc.1991.176.
10
Myelodysplastic syndrome as a complication of neo-adjuvant triple M chemotherapy and radiotherapy.骨髓增生异常综合征作为新辅助三联M化疗和放疗的并发症。
Clin Oncol (R Coll Radiol). 1999;11(3):187-9. doi: 10.1053/clon.1999.9039.
引用本文的文献
1
Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma.基于米托蒽醌的乳腺癌治疗后发生的继发性骨髓增生异常综合征/急性髓系白血病
Br J Cancer. 2000 Jul;83(1):91-4. doi: 10.1054/bjoc.2000.1196.
2
Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy.常见的NAD(P)H醌氧化还原酶多态性患病率的种族差异及其对抗癌化疗的影响。
Br J Cancer. 1997;76(7):852-4. doi: 10.1038/bjc.1997.474.
Zotero 插件